Pulmonary Nodules
Conditions
Brief summary
Computed tomography (CT) is critical for the diagnosis of lung nodules as well as for therapeutic management. Repeated CT examinations will raise the issue of the cumulative radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques using low or no radiation dose. Magnetic Resonance Imagery (MRI) with ultrashort echo time (UTE) pulse sequences with high signal-to-noise and spatial resolution is a promising alternative for lung nodules imaging.The purpose of the study is to evaluate the value of dynamic contrast-enhanced MR imaging (DCE-MRI) to discriminate of malignant from benign lesions.
Detailed description
Computed tomography (CT) is critical for the diagnosis of lung nodules as well as for therapeutic management. Repeated CT examinations will raise the issue of the cumulative radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques using low or no radiation dose. Magnetic Resonance Imagery (MRI) with ultrashort echo time (UTE) pulse sequences with high signal-to-noise and spatial resolution is a promising alternative for lung nodules imaging.The purpose of the study is to evaluate the value of DCE-MRI to discriminate of malignant from benign lesions.In this study, the investigators are going to validate the efficacy of the DCE-MRI for diagnosing early lung cancer by comparing results of the pre-surgery MRI imaging with the post-surgery pathology.
Interventions
DIAGNOSTIC_TESTMRI scan
All participants will undergo 1 DCE-MRI scan.
Sponsors
Qianfoshan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ground-glass pulmonary nodules found by CT scan * Plan to accept surgery or puncture due to the pulmonary nodules * Absence of treatment such as chemotherapy or radiotherapy and biopsy * Adequate renal function to tolerate intravenous gadolinium * Agree to sign informed consent * Able to lie still during DCE-MRI
Exclusion criteria
* Fail to understand or agree to sign informed consent * Implanted pacemaker or cardiac defibrillator * Contraindications to undergoing MRI * Uncontrolled intercurrent illness * Pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume transfer constant (Ktrans) | 12 months | Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI. |
| the fractional volume of extravascular extracellular space of the target tissue (ve) | 12 months | Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI. |
| the rate constant (kep) | 12 months | Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI. |
Outcome results
None listed